RAF1 and hepatocellular carcinoma: Frequent activation of the MAPK/ERK signaling pathway in HCC is explained not so much by RAS and RAF mutations as by alternative mechanisms such as aberrant activation of upstream growth factors and receptors, downregulation of negative regulators of the MAPK/ERK signaling pathway, or upregulation of its positive modulators.